1. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
- Author
-
Camila R. R. Pão, Thomas Tuschl, Aitor Garzia, Lucas Villas Bôas Hoelz, Felipe Betoni Saraiva, Suelen da Silva Gomes Dias, Dumith Chequer Bou-Habib, Frederico Silva Castelo Branco, Wei Xie, Jingyue Ju, Chuanjuan Tao, Vinicius Cardoso Soares, André C. Ferreira, Stevens K. Rehen, Jairo R. Temerozo, Caroline S. de Freitas, Carine dos Santos da Silva, Carolina Q. Sacramento, Marília Zaluar P. Guimarães, Andrew Owen, Thiago Moreno L. Souza, Patrícia T. Bozza, Xuanting Wang, Nubia Boechat, Mayara Mattos, Rajith K. R. Rajoli, Dinshaw J. Patel, Steffen Jockusch, Marcelo Alves Ferreira, Fernando A. Bozza, Natalia Fintelman-Rodrigues, Gabriela Vitória, Livia Goto-Silva, Tácio Vinício Amorim Fernandes, Aline de Paula Dias Da Silva, Mônica M. Bastos, Carolina da S. G. Pedrosa, Leticia R. Q. Souza, James J. Russo, and Minchen Chien
- Subjects
0301 basic medicine ,Microbiology (medical) ,Pyrrolidines ,Daclatasvir ,Sofosbuvir ,viruses ,Biology ,Pharmacology ,Antiviral Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,RNA polymerase ,Chlorocebus aethiops ,medicine ,AcademicSubjects/MED00740 ,Animals ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,NS5A ,Vero Cells ,NS5B ,Original Research ,SARS-CoV-2 ,Imidazoles ,COVID-19 ,virus diseases ,RNA ,Valine ,biochemical phenomena, metabolism, and nutrition ,In vitro ,AcademicSubjects/MED00290 ,030104 developmental biology ,Infectious Diseases ,Pharmaceutical Preparations ,chemistry ,Vero cell ,RNA, Viral ,Carbamates ,AcademicSubjects/MED00230 ,medicine.drug - Abstract
Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality. SARS-CoV-2 nsp12, its RNA polymerase, shares homology in the nucleotide uptake channel with the HCV orthologue enzyme NS5B. Besides, HCV enzyme NS5A has pleiotropic activities, such as RNA binding, that are shared with various SARS-CoV-2 proteins. Thus, anti-HCV NS5B and NS5A inhibitors, like sofosbuvir and daclatasvir, respectively, could be endowed with anti-SARS-CoV-2 activity. Methods SARS-CoV-2-infected Vero cells, HuH-7 cells, Calu-3 cells, neural stem cells and monocytes were used to investigate the effects of daclatasvir and sofosbuvir. In silico and cell-free based assays were performed with SARS-CoV-2 RNA and nsp12 to better comprehend the mechanism of inhibition of the investigated compounds. A physiologically based pharmacokinetic model was generated to estimate daclatasvir’s dose and schedule to maximize the probability of success for COVID-19. Results Daclatasvir inhibited SARS-CoV-2 replication in Vero, HuH-7 and Calu-3 cells, with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than daclatasvir, sofosbuvir alone and combined with daclatasvir inhibited replication in Calu-3 cells. Sofosbuvir and daclatasvir prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Sofosbuvir inhibited RNA synthesis by chain termination and daclatasvir targeted the folding of secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial daclatasvir in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Conclusions Daclatasvir, alone or in combination with sofosbuvir, at higher doses than used against HCV, may be further fostered as an anti-COVID-19 therapy.
- Published
- 2021